Nuplazid (Acadia Pharmaceuticals) Drug Overview & Outlook: 2017-2018 to 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Nuplazid" report has been added to ResearchAndMarkets.com's offering.

Nuplazid (Acadia Pharmaceuticals) contains pimavanserin, which is a selective serotonin inverse agonist preferentially targeting the serotonin 5-HT2A receptors. Its novel mechanism of action targets the serotonergic 5-HT2A receptors while avoiding activity at dopamine and other receptors, distinguishing it from other antipsychotics.

Nuplazid is being developed to fulfill a critical unmet need, as it is targeted towards treatment-resistant schizophrenia and negative symptoms. Demonstrating a favorable side-effect profile is vital to Nuplazid's position as it is being developed as an adjunctive therapy in a treatment landscape where physicians constantly select monotherapies over combination regimens. The preference for monotherapies is driven by treatment guidelines.

Given the dubious evidence supporting combination use, the potentially negative compliance, cost, and tolerability implications are considered too weighty to risk for a minor additional benefit in return. Poor tolerability would significantly dampen Nuplazid's prospects, as this would notably fail to differentiate the product from clozapine (the only currently approved therapy for treatment-resistant schizophrenia).

It is believed that demonstrating Nuplazid's superior clinical profile to clozapine represents a key opportunity for the drug to establish a competitive clinical profile.

Key Topics Covered

  1. Overview
  2. Drug Overview
  3. Product Profiles
  4. Nuplazid: Schizophrenia

List of Figures

Figure 1: Nuplazid for schizophrenia - SWOT analysis

Figure 2: Drug assessment summary of Nuplazid for schizophrenia

Figure 3: Drug assessment summary of Nuplazid for schizophrenia

Figure 4: Nuplazid sales for schizophrenia across the US and five major EU markets, by country, 2017-26

List of Tables

Table 1: Nuplazid drug profile

Table 2: Nuplazid Phase II and Phase III trials in schizophrenia

Table 3: Nuplazid Phase II data in schizophrenia

Table 4: Nuplazid sales for schizophrenia across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/kp58kp/nuplazid_acadia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs